PSMA-PET with 18F-PSMA approved in Switzerland since October 2019. Compared to choline PET, PSMA PET has a significantly higher sensitivity for lymph node and distant metastases and, in contrast to choline PET, can also be used well for initial staging in prostate cancer.
Coronary MIP uptake in this 67-year-old patient provides a first overall view. After a radical prostate resection in 2013, the PSA increased again to currently 0.22 ng/ml. Axial fused images demonstrate focal PSMA enhancement in a pararectal lymph node as small as 3 mm in diameter (yellow arrow). This is therefore, despite the small size suspicious for a lymph node metastasis.
The following indication is reimbursed by the health insurance:
Senior Attending Physician, Vice Director of the Institute, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.
Simply assign your patient via registration form.
Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02